Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
Clinical Colorectal Cancer · 2023-03 · 22 (1) · 100-110
DOI: 10.1016/j.clcc.2022.11.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Colorectal Cancer, 2023-03. Verfasst von Manish A Shah und 19 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, NY; New York-Presbyterian Hospital, New York, NY. Electronic address: mas9313@med.cornell.edu. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Sumitomo Dainippon Pharma Oncology, Dainippon Sumitomo Pharma Co Ltd.
Abstract (Originalsprache)
PURPOSE: Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone oxidoreductase 1 that has been evaluated in various solid tumors, including metastatic colorectal cancer (mCRC). Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is hypothesized to predict response in napabucasin-treated patients with mCRC. PATIENT AND METHODS: In the multi-center, open-label, phase III CanStem303C (NCT02753127) study, adults with histologically confirmed mCRC that progressed on first-line fluoropyrimidine plus oxaliplatin ± bevacizumab were randomized to twice-daily napabucasin plus FOLFIRI (napabucasin) or FOLFIRI alone (control). The primary endpoint was overall survival (OS) in the general study population and in patients with pSTAT3-positive tumors (biomarker-positive). RESULTS: In the general study population (napabucasin, n = 624; control, n = 629), median OS was 14.3 months for napabucasin and 13.8 months for control (hazard ratio [HR], 0.976, one-sided P = .74). Overall, 44% of patients were biomarker-positive (napabucasin, n = 275; control, n = 272). In the biomarker-positive population, median OS was 13.2 months for napabucasin and 12.1 months for control (HR, 0.969; one-sided P > .99). In the control arm, median OS was shorter for biomarker-positive versus biomarker negative patients (12.1 vs. 18.5 months; HR, 1.518; nominal 2-sided P = .0002). The most common treatment-emergent adverse events (TEAEs) were diarrhea (napabucasin, 84.6%; control, 53.9%), nausea (60.5%, 50.5%), vomiting (41.2%, 29.3%), and abdominal pain (41.0%, 25.2%). Grade ≥3 TEAEs occurred in 73.8% of napabucasin-treated and 66.7% of control-treated patients, most commonly diarrhea (21.2%, 7.0%), neutrophil count decreased (13.7%, 19.2%), and neutropenia (13.3%, 15.2%). Safety was similar in biomarker-positive patients. CONCLUSION: In patients with previously treated mCRC, adding napabucasin to FOLFIRI did not improve OS. Results from the control arm indicate that pSTAT3 is an adverse prognostic factor in mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medicine, New York, NY; New York-Presbyterian Hospital, New York, NY. Electronic address: mas9313@med.cornell.edu.
- National Cancer Center Hospital East (NCCE), Kashiwa, Japan.
- Department of Medical Oncology, Austin Health, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
- West Cancer Center and Research Institute, Germantown, TN.
- Vall d'Hebron Hospital, Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic- UCC, Barcelona, Spain.
- Sun Yat-sen University Cancer Center, Guangzhou, China.
Förderung
- Sumitomo Dainippon Pharma Oncology
- Dainippon Sumitomo Pharma Co Ltd
Zitieren
APA
Shah, M. A., Yoshino, T., Tebbutt, N. C., Grothey, A., Tabernero, J., Xu, R. H., Cervantes, A., Oh, S. C., Yamaguchi, K., Fakih, M., Falcone, A., Wu, C., Chiu, V. K., Tomasek, J., Bendell, J., Fontaine, M., Hitron, M., Xu, B., Taieb, J., & Van Cutsem, E. (2023). Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. Clinical Colorectal Cancer, 22(1), 100-110. https://doi.org/10.1016/j.clcc.2022.11.002
Vancouver
Shah MA, Yoshino T, Tebbutt NC, Grothey A, Tabernero J, Xu RH, et al. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. Clinical Colorectal Cancer. 2023;22(1):100-110. doi:10.1016/j.clcc.2022.11.002
BibTeX
@article{Shah2023,
author = {Shah, Manish A and Yoshino, Takayuki and Tebbutt, Niall C and Grothey, Axel and Tabernero, Josep and Xu, Rui-Hua and Cervantes, Andres and Oh, Sang Cheul and Yamaguchi, Kensei and Fakih, Marwan and Falcone, Alfredo and Wu, Christina and Chiu, Vi K and Tomasek, Jiri and Bendell, Johanna and Fontaine, Marilyn and Hitron, Matthew and Xu, Bo and Taieb, Julien and Van Cutsem, Eric},
title = {Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study},
journal = {Clinical Colorectal Cancer},
year = {2023},
volume = {22},
number = {1},
pages = {100--110},
doi = {10.1016/j.clcc.2022.11.002}
}
EUVIMED